TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00651820
Drug: Collagenase Santyl Vehicle
Normalized name: collagenase Topical Ointment [Santyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatome-induced skin wounds treated with Vehicle alone. Each subject serves as his own control receiving both treatments in parallel.
Study: NCT00069927
Drug: Adderall-XR®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adderall-XR® 10 mg/day for 3-12 weeks depending on subject's response
Study: NCT00069927
Drug: Concerta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concerta® 18 mg/day for 3-12 weeks depending on subject's response
Study: NCT00584025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min
Study: NCT01854047
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, Subcutaneous injection
Study: NCT01854047
Drug: ICS/LABA therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
Study: NCT00625989
Drug: Aeroallergen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00054704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02303366
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
Study: NCT00758836
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00758836
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01019889
Drug: SCRT
Normalized name: ExoSCRT Derma Signal Kit SRLV KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules,three times daily, for 7days or within symptom disappearance
Study: NCT01019889
Drug: YPS
Normalized name: Lypsyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules, three times daily, for 7days or within symptom disappearance
Study: NCT01019889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules, three times daily, for 7days or within symptom disappearance
Study: NCT00592930
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01077596
Drug: Regular TCA (Tricyclic antidepressants) use
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
Study: NCT01077596
Drug: Regular use of any other antidepressant
Normalized name: ANTIDEPRESSANTS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An other antidepressant would be any antidepressant other than bupropion, a SSRI or a TCA.
Study: NCT00430196
Drug: BOTOX®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01880593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm take placebo pills at night for duration of the study.
Study: NCT02445339
Drug: XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention arm will receive extended-release naltrexone (XR-NTX) 380mg (4 mL) to be administered as an intramuscular gluteal injection every 28 days up to 12 doses total. Expedited referral to alcohol-medical management. Care Management will include coordination of health care and social services for at least 12 months. Harm-reduction counseling and motivational interviewing to identify and work towards goals. The Standard care arm will receive an expedited alcohol-medical management referral.
Study: NCT01161615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of up to two patches for up to 7 days.
Study: NCT04003350
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam 15 mg as need once per day
Study: NCT01820208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
Study: NCT03872947
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenously over 30 - 90 minutes
Study: NCT03872947
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously over 60 minutes
Study: NCT01101022
Drug: SPD489
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
Study: NCT00816595
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00036517
Drug: PHY906
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00934492
Drug: Placebo dispersible tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dispersible tablets 120/240mg daily for six consecutive months.
Study: NCT00552565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01688934
Drug: Naproxen 500-mg capsules
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally twice daily
Study: NCT01688934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
Study: NCT04167267
Drug: DWP14012 tablet A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
Study: NCT04167267
Drug: DWP14012 tablet B
Normalized name: ACTION B-100 TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
Study: NCT03555929
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
Study: NCT02701296
Drug: Ropivacaine with Epinephrine
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior capsular injection - ultrasound guided infiltration of Ropivacaine with Epinephrine between popliteal artery and capsule of knee above the femoral condyles
Study: NCT04092751
Drug: PRA
Normalized name: PRAI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 20-mg dose of PRA on Day 1 AM
Study: NCT01136382
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pMDI, inhalation, bid, 6 weeks
Study: NCT02639741
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative melatonin tablet will be given and postoperative pain scores will be evaluated
Study: NCT01309542
Drug: Desvenlafaxine Succinate
Normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months
Study: NCT03349775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
Study: NCT00000570
Drug: pulmonary surfactant
Normalized name: Pulmonary surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03416270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 12 weeks
Study: NCT04106882
Drug: Ketones
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement administered mid-scan.
Study: NCT00262223
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01892722
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule required for double-dummy masking to blind formulations.
Study: NCT01892722
Drug: Placebo i.m. injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo i.m. injection required for double-dummy masking to blind formulations.
Study: NCT03977233
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle
Study: NCT04186819
Drug: rhPSMA-7.3 (18F) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand for PET CT scanning
Study: NCT04224558
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stem Cell Mobilization:~Cyclophosphamide (CY) infused intravenously over 1 hour: 50 mg/kg (25 mg/kg/day on 2 consecutive days)
Study: NCT04224558
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparative/Conditioning Regime r-ATG premedication according to institutional guidlines
Study: NCT04224558
Drug: lymphocyte immune globulin
Normalized name: lymphocyte immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparative/Conditioning Regime In patients who develop severe allergic reactions to rATG (Thymoglobulin), it may be substituted by horse ATG (hATG, ATGAM, Pharmacia \& Upjohn, Kalamazoo, MI). The recommended dose of hATG is 25 mg/kg/day for 3 doses.
Study: NCT00029874
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01049334
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
Study: NCT02603224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.
Study: NCT01297348
Drug: 90ug levonorgestrel / 20 ug ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
Study: NCT01297348
Drug: Oral Contraceptives containing 20 ug of ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
Study: NCT01628445
Drug: placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injected sc daily volume equal to active comparator
Study: NCT01845831
Drug: Basal Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
Study: NCT02991404
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.125% bupivacaine
Study: NCT01175616
Drug: Creatine
Normalized name: Creatine
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Creatine 5 grams daily.
Study: NCT01845831
Drug: Glargine 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glargine will be prescribed at 50% of daily hospital dose.
Study: NCT01845831
Drug: Glargine 80%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glargine will be prescribed at 80% of daily hospital dose.
Study: NCT02229968
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02745990
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal salin is administered the same volume with rhEPO intravenously within 72h after birth, and every other day up to 32 weeks of corrected age..
Study: NCT01585259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT02188953
Drug: ACCS100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACCS100 is made from Hydrated Sodium Calcium Aluminosilicate, which is a substance generally recognized as safe by the U.S. FDA.
Study: NCT01516970
Drug: NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: The NRTIs (including tenofovir/emtricitabine \[Truvada\], lamivudine/zidovudine \[Combivir\]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.
Study: NCT02188953
Drug: Calcium carbonate placebo
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01572116
Drug: Lidocaine with Epinephrine+ Normal saline
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline
Study: NCT01572116
Drug: Lidocaine with Epinephrine + sufentanil
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
Study: NCT03973515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet
Study: NCT02336958
Drug: pericarotidal infiltration (placebo comparator) saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
Study: NCT00476736
Drug: Effect on small airways (N-Acetylcystein)
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00514514
Drug: Simulect®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
Study: NCT00760019
Drug: salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 grams orally 3 times daily
Study: NCT00760019
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT02685462
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02685462
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02685462
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03537144
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV indomethacin will be given every 12 hours for 3 doses. If \<48 hours old, 1st dose 0.2 mg/kg, 2nd dose 0.1 mg/kg, and 3rd dose 0.1mg/kg. If 2-7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.2 mg/kg, and 3rd dose 0.2 mg/kg. If \>7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.25 mg/kg, and 3rd dose 0.25 mg/kg.
Study: NCT03537144
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/kg/dose every 6 hours for 12 doses
Study: NCT04092712
Drug: [14C]-CTP-543
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution
Study: NCT01281501
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.9% sodium chloride solution
Study: NCT01281501
Drug: Oral antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)
Study: NCT03156920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study: NCT02724254
Drug: AP611074 5% gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02672436
Drug: ENERGI-F703
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.
Study: NCT02672436
Drug: ENERGI-F703 matched vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
Study: NCT02424942
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular
Study: NCT02424942
Drug: GZ389988
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:suspension for injection~Route of administration: intraarticular
Study: NCT00833339
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00975299
Drug: BAY86-4367
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT
Study: NCT00975299
Drug: BAY86-4367
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
Study: NCT02187172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04264130
Drug: Artemether-Lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects received artemether-lumefantrine according to their body weight twice per day for three days.
Study: NCT00345839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
Study: NCT01149473
Drug: Losartan potassium/Hydrochlorothiazide
Normalized name: losartan potassium/hydrochlorothiazide 100 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100/25 mg Tablets
Study: NCT03721744
Drug: GB201
Normalized name: ELECTRIC GREEN BARB TRANSGENIC WHOLE (GB2011 RDNA CONSTRUCT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB201 will be administered orally, twice daily, with doses separated by approximately 8-12 hours. GB201 administration will begin 2-5 days prior to the first infusion of paclitaxel and low-dose gemcitabine
Study: NCT01133353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 5 tablets once per day depending on weight for 12 weeks
Study: NCT01901705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo was a mixture of blue dye powder (54.8% Indigo carmine aluminum lake \[Blue #32\] and 45.2% Allura Red AC aluminum lake \[Red #40\] powders), Vaseline, microcrystalline wax, and olive oil.
Study: NCT02535715
Drug: ORMD-0801 capsules- 2x8mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who receive this intervention first, then receive either ORMD-0801- 3x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
Study: NCT02535715
Drug: ORMD-0801 capsules- 3x8mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
Study: NCT02535715
Drug: ORMD-0801 capsules- 1x16mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 3x8mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
Study: NCT01032837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo provided as capsules and as a suspension.
Study: NCT00139776
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.~Placebo used as flare medication when directed.
Study: NCT00139776
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.~Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.
Study: NCT05244759
Drug: [14C]-BLU-5937
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state.
Study: NCT00497107
Drug: UFT, Calcium Folinate, PSK
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00497107
Drug: UFT, Calcium Folinate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04119921
Drug: prescription topical ketorolac in group 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
Study: NCT00914927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or inactive substance once a day for up to 7 days